About Richard Hague
Richard Hague is a director at Omeza.
Form D filings also name Richard Hague as a board member at Remedium Bio.
Richard Hague reports to the SEC as an officer of 2 public companies: Polarityte (PTE) and Anika Therapeutics (ANIK).
Richard Hague first appears on SEC filings in 2015.
Experience
This experience comes from Richard Hague's profile and from SEC filings. For roles taken from filings, the years are when the filings name Richard Hague in the role, so the role may have started earlier or lasted longer.
Remedium Bio Inc. Current
Board Member
2022 – Present · Needham, MA
Develops gene therapies for people with chronic diseases.
RE
RegenETP
CEO & Chairman
2023 – 2025
PI
Polarityte, Inc.
Chf. Exec. Off. & Pres
President & Chief Executive Officer (2019 – 2023)
2019 – 2023 · Public company (PTE)
BI
BioUtah
Board Member
2020 – 2022
AI
Anika Therapeutics, Inc.
Chief Commercial Officer
2015 – 2019 · Public company (ANIK)
TI
TEI Medical Inc.
Vice President Sales and Marketing
2014 – 2015
SG
Sanofi Genzyme
VP/GM
2011 – 2014
GE
Genzyme
Sales & Marketing Leadership Positions - BioSurgery
1996 – 2011
PH
Pfizer - Howmedica
Orthopedic Sales and Sales Training
1989 – 1996
JJ
Johnson & Johnson
Orthopedic Sales
1987 – 1989
Key Colleagues at Startups
The people Richard Hague works with at each company, as listed on that company's latest Form D.
Remedium Bio Inc. · Form D, May 18, 2026
Alexei Goraltchouk
Chief Technology Officer and director
Frank Luppino
President and CEO, director
Harry Robb
Board Member
Omeza Holdings, Inc. · Form D, Jan 10, 2025